Fiche publication
Date publication
février 2023
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Dr ARNOULD Laurent
,
Dr BOIDOT Romain
,
Pr GHIRINGHELLI François
,
Dr LADOIRE Sylvain
,
Mme TRUNTZER Caroline
,
Dr DESMOULINS Isabelle
,
Dr HENNEQUIN Audrey
,
Dr MAYEUR Didier
,
Dr GALLAND Loïck
,
Dr REDA Manon
,
Dr ALBUISSON Juliette
Tous les auteurs :
Galland L, Roussot N, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Reda M, Albuisson J, Arnould L, Boidot R, Truntzer C, Ghiringhelli F, Ladoire S
Lien Pubmed
Résumé
Breast cancer is the most frequently occurring cancer worldwide. With its increasing incidence, it is a major public health problem, with many therapeutic challenges such as precision medicine for personalized treatment. Thanks to next-generation sequencing (NGS), progress in biomedical technologies, and the use of bioinformatics, it is now possible to identify specific molecular alterations in tumor cells-such as homologous recombination deficiencies (HRD)-enabling us to consider using DNA-damaging agents such as platinum salts or PARP inhibitors. Different approaches currently exist to analyze impairment of the homologous recombination pathway, e.g., the search for specific mutations in homologous recombination repair (HRR) genes, such as /; the use of genomic scars or mutational signatures; or the development of functional tests. Nevertheless, the role and value of these different tests in breast cancer treatment decisions remains to be clarified. In this review, we summarize current knowledge on the clinical utility of genomic tests, evaluating HRR deficiency for treatment decisions in early and metastatic breast cancer.
Mots clés
BRCA, HRD score, NGS, PARPi, breast cancer, early breast cancer, homologous recombination deficiency, metastatic breast cancer, mutational signature, platinum salts
Référence
Cancers (Basel). 2023 02 18;15(4):
